Revenue: As of FY2026 Q1, the actual value is USD 353.38 K.EPS: As of FY2026 Q1, the actual value is USD -0.28.EBIT: As of FY2026 Q1, the actual value is USD -1.183 M.<h4>Segment Revenue</h4>For the three months ended March 31, 2026, 20⁄20 Biolabs, Inc.’s total revenues decreased by $200,445, or 36.19%, to $353,375 from $553,820 in the prior year period.<ul><li>OneTest: Revenues decreased by $161,276, or 34.21%, to $310,103 (87.75% of total revenues) for the three months ended March 31, 2026, compared to $471,379 (85.11% of total revenues) for the same period in 2025. This decrease was primarily due to a significant fire department customer’s renewal being delayed from the first quarter of 2025 to the second quarter of 2026.</li><li>BioCheck: Revenues decreased by $35,420, or 62.18%, to $21,547 (6.10% of total revenues) for the three months ended March 31, 2026, from $56,967 (10.29% of total revenues) in the prior year period. This decline is attributed to a years-long trend following patent expiration in 2021 and increased competition.</li><li>CLIAx: Revenues decreased by $3,749, or 14.72%, to $21,725 (6.15% of total revenues) for the three months ended March 31, 2026, from $25,474 (4.60% of total revenues) in the prior year period. This decrease was mainly due to the timing of work performed related to CLIAx client operations.</li></ul><h4>Operational Metrics</h4><ul><li>Cost of Revenues: Decreased by $97,534, or 25.14%, to $290,491 for the three months ended March 31, 2026, from $388,025 in the prior year. As a percentage of revenues, cost of revenues increased to 82.20% in 2026 from 70.06% in 2025, primarily due to decreased revenues from OneTest and BioCheck while fixed costs remained relatively stable.</li><li>Gross Profit: Decreased by $102,911, or 62.07%, to $62,884 for the three months ended March 31, 2026, from $165,795 in the prior year.</li><li>Gross Margin: Decreased to 17.80% for the three months ended March 31, 2026, from 29.94% in the prior year.</li><li>Sales, General and Administrative Expenses: Increased by $551,614, or 68.85%, to $1,352,758 for the three months ended March 31, 2026, from $801,144 in the prior year. This increase was primarily due to expenses associated with the company’s direct listing on Nasdaq.</li><li>Research and Development Expenses: Increased by $16,651, or 12.17%, to $153,482 for the three months ended March 31, 2026, from $136,831 in the prior year. This increase was primarily due to further development of the longevity test, launched in the first quarter of 2026.</li><li>Operating Loss: Increased to - $1,443,356 for the three months ended March 31, 2026, from - $772,180 in the prior year.</li><li>Net Loss: Increased by $1,410,259, or 184.45%, to - $2,174,836 for the three months ended March 31, 2026, from - $764,577 in the prior year.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: - $1,288,960 for the three months ended March 31, 2026, compared to - $488,293 in the prior year. This was mainly attributed to the net loss and non-cash adjustments including stock-based compensation, amortization of debt discount, loss on issuance of convertible debt, and change in fair value of derivative liability.</li><li>Net Cash Used in Investing Activities: - $5,354 for the three months ended March 31, 2026, consisting of patent costs, with no investing activities in the prior year period.</li><li>Net Cash Provided by Financing Activities: $4,487,426 for the three months ended March 31, 2026, compared to $262,338 in the prior year. This included $5,000,000 from Series E preferred stock issuance and $250,000 from convertible notes, offset by $737,574 in offering costs.</li></ul><h4>Future Outlook and Strategy</h4>20⁄20 Biolabs, Inc. anticipates continued operating losses in the near term. To support ongoing operations and liquidity, the company raised $5 million through a private placement and $275,000 through convertible debt and bridge financing post-December 31, 2025. The company also completed a direct listing on Nasdaq as part of its capital-raising and strategic growth initiatives, though there is no assurance this will generate sufficient liquidity.

20/20 Biolabs | 10-Q: FY2026 Q1 Revenue: USD 353.38 K